Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Genetic research into the select agents Burkholderia pseudomallei and B. mallei is currently hampered by a paucity of approved antimicrobial drug-selection markers. The strict regulations imposed on researchers in the United States but not in other parts of the world lead to discrepancies in practice, hinder distribution of genetically modified strains, and impede progress in the field. Deliberation and decisions regarding alternative selection markers (antimicrobial and nonantimicrobial drugs) by the international community, regulatory authorities, and funding agencies are needed.

Original publication

DOI

10.3201/eid1411.080431

Type

Journal article

Journal

Emerging infectious diseases

Publication Date

11/2008

Volume

14

Pages

1689 - 1692

Addresses

Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. herbert.schweizer@colostate.edu

Keywords

Animals, Humans, Burkholderia mallei, Burkholderia pseudomallei, Genetic Markers, Anti-Bacterial Agents, Microbial Sensitivity Tests, Drug Resistance, Bacterial, Selection, Genetic